a Protein and mRNA expression of HER-2 in the same four breast cancer cell lines after rVP1 treatment at 37°C for 24 h in serum-free medium. Actin was used as a loading control. b Cell migration/ invasion of breast cancer cells after rVP1 treatment at 37°C for 24 h using Transwell migration assay. The results were reproduced in three independent experiments. Data represent mean ± SD (n = 3). *P \ 0.05; **P \ 0.01. c rVP1-pretreated breast cancer cells implanted intravenously via the tail vein. All mice (n = 4/group) were sacrificed at day 14 after inoculation. Gross and histopathologic appearances of lung and lung weight and the number of tumor foci in lung showed that rVP1 treatment suppressed metastasis of breast cancer cells to the lung in the classic experimental metastasis models. Data represent mean ± SD (n = 4). *P \ 0.05; **P \ 0.01; ***P \ 0.001. White scale bar 1 cm; black scale bar 5 lm Fig. 5 rVP1 treatment suppresses breast cancer metastasis in a murine orthotopic TS/A breast cancer allograft model. a The diagram depicts the timeline for orthotopic implantation of TS/A breast cancer cells, and the rVP1-therapy strategy: 1 or 25 mg/kg BW rVP1 by iv injection, three times/week for 4 weeks. The therapeutic periods were: early therapy (D1-D30), and late therapy (D31-D60). Three mice per group (n = 12/group) were sacrificed at the end point of each therapeutic period. The survival of the remaining mice was monitored. b Early therapy: gross appearance and the weight of orthotopic tumor mass were evaluated after 1 or 25 mg/kg BW rVP1 treatment. Data represent mean ± SD (n = 3). **P \ 0.01 (vehicle group vs. rVP1-treated group). c Early therapy: gross and histopathologic appearances of lung and lung weight and the number of tumor foci in lung showed that rVP1 treatment suppressed metastasis of breast cancer cells to the lung. Arrows show tumor foci in lung. Data represent mean ± SD (n = 3). *P\0.05; ***P\0.001 (vehicle group vs. rVP1-treated group). ''N'' represents normal status of mice. ''V'' represents tumor implantation without rVP1 treatment. d Late therapy: the gross appearance and weight of orthotopic tumor mass was evaluated after 1 or 25 mg/kg BW rVP1 treatment. Data represent mean ± SD (n = 3). **P \0.01 (vehicle group vs. rVP1-treated group). e Late therapy: the gross and histopathologic appearances of lung were evaluated after rVP1 treatment. Gross and histopathologic appearances of lung and lung weight and the number of tumor foci in lung showed that rVP1 treatment suppressed metastasis of breast cancer cells to the lung. Arrows show tumor foci in lung. Data represent means ± SD (n = 3). ***P\0.001 (vehicle group vs. rVP1-treated group). f The survival of tumor-bearing mice was monitored after ''early'' and ''late'' rVP1 therapy (n = 9). **P \ 0.01; ***P \ 0.001. The experiment was performed twice and data are from one representative experiment
